BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35730438)

  • 1. The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease.
    Deng I; Garg S; Zhou XF; Bobrovskaya L
    Front Biosci (Schol Ed); 2022 May; 14(2):13. PubMed ID: 35730438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice.
    Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-1β/IL-1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha-Synuclein pathology in the olfactory bulb, substantia nigra and striatum.
    Niu H; Wang Q; Zhao W; Liu J; Wang D; Muhammad B; Liu X; Quan N; Zhang H; Zhang F; Wang Y; Li H; Yang R
    Brain Pathol; 2020 Nov; 30(6):1102-1118. PubMed ID: 32678959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin affords neuroprotection and inhibits α-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model.
    Sharma N; Nehru B
    Inflammopharmacology; 2018 Apr; 26(2):349-360. PubMed ID: 29027056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Cui C; Han Y; Li H; Yu H; Zhang B; Li G
    Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.
    Yuan WJ; Yasuhara T; Shingo T; Muraoka K; Agari T; Kameda M; Uozumi T; Tajiri N; Morimoto T; Jing M; Baba T; Wang F; Leung H; Matsui T; Miyoshi Y; Date I
    BMC Neurosci; 2008 Aug; 9():75. PubMed ID: 18671880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
    Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
    Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effect of green tea extract (-)-epigallocatechin-3-gallate in a preformed fibril-induced mouse model of Parkinson's disease.
    Shen J; Xie J; Ye L; Mao J; Sun S; Chen W; Wei S; Ruan S; Wang L; Hu H; Wei J; Zheng Y; Xi Z; Wang K; Xu Y
    Neuroreport; 2024 Apr; 35(6):421-430. PubMed ID: 38526966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson's disease in C57BL/6 mice.
    Deng I; Wiese MD; Zhou XF; Bobrovskaya L
    Neurotoxicology; 2021 Jul; 85():254-264. PubMed ID: 34097939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin protects dopaminergic neurons against inflammation-mediated damage and improves motor dysfunction induced by single intranigral lipopolysaccharide injection.
    Sharma N; Sharma S; Nehru B
    Inflammopharmacology; 2017 Jun; 25(3):351-368. PubMed ID: 28409389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice.
    Tanaka S; Ishii A; Ohtaki H; Shioda S; Yoshida T; Numazawa S
    J Neuroinflammation; 2013 Dec; 10():143. PubMed ID: 24289537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model.
    He Q; Li YH; Guo SS; Wang Y; Lin W; Zhang Q; Wang J; Ma CG; Xiao BG
    Eur J Neurosci; 2016 Jan; 43(1):41-52. PubMed ID: 26565388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson's disease.
    Izco M; Blesa J; Verona G; Cooper JM; Alvarez-Erviti L
    Neurosci Res; 2021 Sep; 170():330-340. PubMed ID: 33316306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
    Xue YQ; Zhao LR; Guo WP; Duan WM
    Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson's disease mouse model.
    Mobahat M; Sadroddiny E; Nooshabadi VT; Ebrahimi-Barough S; Goodarzi A; Malekshahi ZV; Ai J
    Cell Tissue Bank; 2023 Mar; 24(1):75-91. PubMed ID: 35641803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of preconditioning with low dose of LPS on paraquat-induced neurotoxicity, microglia activation and expression of α-synuclein and synphilin-1 in the dopaminergic system.
    Kuter KZ; Śmiałowska M; Ossowska K
    Pharmacol Rep; 2022 Feb; 74(1):67-83. PubMed ID: 34762280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal Carnosine Mitigates α-Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinson's Disease.
    Brown JM; Baker LS; Seroogy KB; Genter MB
    ACS Chem Neurosci; 2021 Jul; 12(13):2347-2359. PubMed ID: 34138535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson's Disease Model in Mice.
    Mani S; Sekar S; Barathidasan R; Manivasagam T; Thenmozhi AJ; Sevanan M; Chidambaram SB; Essa MM; Guillemin GJ; Sakharkar MK
    Neurotox Res; 2018 Apr; 33(3):656-670. PubMed ID: 29427283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.